Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed…
Browsing: Other
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85%of newly diagnosed…
Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85% of newly…
Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.
Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL:…
Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally…
Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC…
Fumito Ito, MD, PhD of Roswell Park @RoswellPark discusses CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1…
Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell…
Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with…
Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with…
Eyal Lebel, MD of Princess Margaret Cancer Centre @pmcancercentre discusses the rare recurrence of cutaneous anaplastic large cell lymphoma. Read…
Adilia Hormigo, MD of Mount Sinai Health System @MountSinaiNYC discusses the clinical study of the safety and tolerability of laser…
Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and…
Yuman Fong, MD surgical oncologist at City of Hope @cityofhope discusses the phase 1a/1b, open-label first-in-human study of the safety, tolerability, and…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research and Jonathan Pachter, PhD of Verastem Oncology discuss the new…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a…
Udai Banerji, MD @udai_banerji of The Institute of Cancer Research discusses the phase 1 study of the combination of a…
Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways:…
Laurie Schenkel of Ribon Therapeutics @RibonTx discusses a potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways.…
Melissa Vasbinder of Ribon Therapeutics @RibonTx discusses a first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways.…
Earn CME: https://www.naccme.com/program/19-cpc-101-7 This webcast features a presentation by Dr. Gary H. Lyman that examines the potential benefits of incorporating…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Prakash Bhuyan, M.D., Ph.D. of INOVIO Pharmaceuticals @InovioPharma discusses the Phase 2 VGX-3100 results In patients with HPV-associated Anal Dysplasia.…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Robert Kreitman, MD of @NIHClinicalCntr @NIH discusses the phase II study of cladribine with delayed or concurrent rituximab in patients…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews addresses how the randomized phase IIB trial of proton beam therapy versus intensity-modulated…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews answers if this can be extended to the community on the randomized phase…
Steven Lin, MD, PhD @StevenLin_MDPhD of @MDAndersonNews discusses the randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses fundamental mechanism for other clinical outcomes and phenotypes. ___________ In a new Cleveland…
Moleculin Biotech, Inc., (Nasdaq:Â MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the implications of real-world…
David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers discusses how RWE (real-world evidence)…